Site icon pharmaceutical daily

Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

BusinessWire

Late-breaking data from pivotal Phase 3 CheckMate -577 and CheckMate -649 trials to be featured in ESMO Presidential Symposium III and highlight potential for Opdivo (nivolumab) and Opdivo-based regimens to change standard of care in early and advanced stages of certain esophageal and gastric cancers

Detailed results from CheckMate -9ER, presented in partnership with Exelixis, Inc. and featured in ESMO Presidential Symposium I, and four-year follow-up data from CheckMate -214 underscore the potential of Opdivo-based combinations to significantly improve survival among patients with advanced renal cell carcinoma

Late-breaking patient-reported outcomes from CheckMate -9LA examine impact of Opdivo plus Yervoy (ipilimumab) combined with limited chemotherapy on health-related quality of life in patients with metastatic non-small lung cancer (NSCLC)

Bristol Myers Squibb to Host Virtual Investor Event on Sept 21 to Discuss ESMO Highlights

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research spanning 15 different cancers at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, reinforcing the depth and breadth of its oncology development program, leadership in immuno-oncology and commitment to delivering value to patients and health systems by discovering potential options to improve long-term outcomes in cancer patients. The virtual congress will take place from September 19 to 21, 2020.

Presentations will highlight Bristol Myers Squibb’s research aimed at addressing cancer through clinical data evaluating Opdivo (nivolumab) as an adjuvant therapy, Opdivo plus Yervoy (ipilimumab) as a first-line treatment and Opdivo-based combinations across an expanding range of cancer types with the goal of advancing durable therapeutic outcomes for patients in need.

Bristol Myers Squibb will also present data exploring various novel tumor targets in early-stage pipeline therapies and novel combinations in cancers including non-Hodgkin lymphoma, extensive-stage small cell lung cancer, diffuse large B-cell lymphoma and glioblastoma, and nearly 20 presentations will share health economic and real-world research on the clinical and economic impact of Bristol Myers Squibb’s therapies.

Overall, data from more than 67 company-sponsored studies will be presented at the meeting, including 12 late-breaking abstracts and 14 proffered paper presentations. The volume and diversity of these data highlight the role of Bristol Myers Squibb as a company dedicated to transforming the lives of patients with different types of cancer through science.

Key data being presented by Bristol Myers Squibb and its partners at the ESMO Virtual Congress 2020 include:

Renal Cell Carcinoma

Gastrointestinal Cancers

Lung Cancer

Melanoma

“Bristol Myers Squibb has made important progress in demonstrating the significant impact our treatments can have on long-term survival and patient outcomes in numerous cancers,” said Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb. “New data we are presenting at ESMO will highlight the potential to change the standard of care for certain cancers, demonstrate the value our therapies can bring to patients, and showcase how we are defining the future of medicine. We are also grateful for the tireless support from and collaboration with the cancer community, especially from investigators and patients, without whom our research would not be possible.”

Virtual Investor Event

Bristol Myers Squibb will host a virtual Investor Event on Monday, September 21, 2020 at 4:30 p.m. EDT to discuss data presented at the European Society of Medical Oncology (ESMO). Company executives will provide an overview of data presented and address questions from investors and analysts.

Investors and the general public are invited to listen to a live webcast at http://investor.bms.com or by calling the U.S. toll free at 800-289-0571 or international +1 313-209-6672, confirmation code: 7966221, or using this link, which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Materials related to the webcast will be available at the same website prior to the event. An archived edition of the session will be available later that day.

Select Bristol Myers Squibb studies at the ESMO Virtual Congress 2020 include:

*All times noted are Central European Summer Time (CEST)

Gastrointestinal

Genitourinary

Lung Cancer

Melanoma

Early Assets

Safety

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering potential new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

INDICATIONS

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Contacts

Bristol Myers Squibb
Media Inquiries:
Media@BMS.com
609-252-3345

Investors:
Tim Power

609-252-7509

timothy.power@bms.com

Nina Goworek

908-673-9711

nina.goworek@bms.com

Read full story here

Exit mobile version